Our commitment is first and foremost to the community of people living with or affected by diabetes or other conditions of glycemic dysregulation. Beta Bionics is proud to be incorporated as a Massachusetts public benefit corporation and certified as a B Corporation®. We believe we were one of the first, if not the first medical device company to be doing business as a benefit corporation, and we’re fairly certain that Beta Bionics is the first company to do so in the diabetes space. We believe the same is true for our B Corporation® certification.
BLACK DIAMOND THERAPEUTICS
Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. The cornerstone of our approach derives from evolving trends in cancer clinical medicine. Genome-wide information – now routinely obtained from DNA testing of cancer patients – identifies clusters of uncharacterized genomic alterations. Today, new baskets of un-drugged oncogenic targets exist, leading to the identification of additional cancer patients in need of novel therapies. Using our MAP platform, Black Diamond Therapeutics is pioneering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets, and to develop novel approaches to creating highly selective therapeutics.
We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases. Finding the right starting points to target diseases at their source.
Using a combination of a systematic assessment of the genetic disease landscape and informed diligence on the latest research, we find indications with clear mechanisms of pathogenesis that are ripe for translation into disease-modifying drugs.
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. A team of scientists with a proven track record of endocrine drug discovery and development founded the company to create important new therapeutic options for endocrinologists and their patients.
IDEAYA is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, the Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by three Members of the National Academy of Sciences.
Kodiak is a high-science retinal medicines development company. We are aspiring to build a dominant global retina franchise. We are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. Our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. In our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments.
Landos’ unique core platform technology enables accelerated development of safer, more effective oral, first-in-class therapeutics for autoimmune diseases. Landos has identified Lanthionine Synthetase C-Like 2 (LANCL2) as a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile.
MeiraGTx, a clinical-stage gene therapy company with a global footprint, is focused on developing potentially curative treatments for patients living with serious diseases. MeiraGTx is pioneering transformative technologies that allow precise control of gene expression using proprietary oral small molecules. Their gene regulation platform includes synthetic riboswitches, rationally designed for mammalian cells. This gene regulation system provides an unprecedented platform for spatial and temporal control of gene therapy, with broad implications for the applicability of genetic medicines for treating a wide range of potential disorders not limited to inherited diseases.
Outset Medical is focused on reimagining the experience of dialysis care for patients with kidney disease by providing them greater flexibility, independence, and control with the potential to dramatically lower cost for providers and the healthcare system.
QSpex is transforming the vision industry by combining best-in-class lens technology with an unprecedented level of service. Transforming the optical industry by offering premium prescription eyewear, fulfilled SAME-DAY, through a personalized delivery and dispensing process. Our high-speed, proprietary Rapid Lens Technology™ eliminates the pitfalls of traditional lens manufacturing. Using QSpex’s groundbreaking Touchless Transfer™ lens system, Rapid Lens Technology™ provides premium prescription eyewear through unique, covalently bonded treatments.
Renovia was formed to better diagnose, treat, and potentially improve the lives of millions of women through a platform of innovative sensor technologies combined with a digital health platform. This allows precise, cost-effective visualization and treatment of weakened pelvic floor muscles in real time, while collecting actionable compliance and progress data on women’s pelvic health. Restoring pelvic health by strengthening pelvic floor muscles through clinically benefiting solutions is paramount to treating the underlying causes of Pelvic Floor Disorders.
A private company focused on acquiring and developing disease modifying therapies for Duchenne Muscular Dystrophy through rigorous scientific analysis, efficient capital management and global collaborations.
Tivorsan Pharmaceuticals is a protein therapeutics company pioneering a unique approach to treat serious neuromuscular disorders, including Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).
Vapotherm is dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery cost and improve quality of life for patients. Vapotherm High Flow Therapy provides support for patients in respiratory distress and has been used in over half a million patients.
Vensun Pharmaceuticals is an emerging generic pharmaceutical company developing a portfolio of difficult to access or hard to formulate generic prescription products.
Verrica Pharmaceuticals is a clinical-stage pharmaceutical company developing proprietary topical therapies for the treatment of skin diseases such as Verruca vulgaris (common warts and plantar warts) and Molluscum contagiosum. Current treatments for these and similar conditions have only limited efficacy, are painful or require daily compliance for an extended treatment period to see results.
Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture. The highly skilled team at Vitruvias has expertise in all aspects of the pharmaceutical industry, including product development, licensing, regulatory affairs, marketing, financial analysis, distribution, managed care, trade relations and sales.
Vyome Biosciences is an innovation driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development.
Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Speciﬁcally, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development.
Acerta Pharma BV is a Biotech company that combines two technology platforms in drug discovery and development: the Covalent Technology Platform and the Multiparametric Phosphoflow Cytometry Platform. These platforms ensure rapid identification and optimization of high-quality drug candidates and enable administering the right drug to the right patient at the right dose.
Bellicum’s CID Technology Enhances Potential of Cellular Immunotherapy Cell signaling switches enable control over immune activity. Bellicum’s unique technology, designed to give physicians control over cells and immune activity inside the body, aims to make cell therapies safer and more effective.
Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
A clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening (“orphan”) inflammatory-fibrotic diseases with clear unmet needs.
GenSight is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
GLOBAL BLOOD THERAPEUTICS (GBT)
Global Blood Therapeutics (GBT) is a clinical stage biopharmaceutical company developing novel small molecule therapeutics to treat grievous, non-malignant blood-based conditions for which there are currently only limited therapy.
Kadmon is a biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. Founded in 2009, Kadmon has pioneered a new approach to the traditional biotechnology model by building, from inception, a vertically integrated company comprising innovative drug discovery platforms, a deep clinical pipeline and a commercial operation with specialty pharmaceutical products.
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Oncobiologics is a complex biosimilar company focused on developing technically challenging biosimilars in a cost effective way. The first wave of Phase 3 ready products include ONS-3010 (Humira® Biosimilar) and ONS-1045 (Avastin® Biosimilar).
Otonomy’s mission is to develop and commercialize novel and best-in-class therapeutics to address unmet medical needs in the emerging otology market, which overcome many of the limitations of delivering drugs to the middle and inner ear.
TRUE NORTH THERAPEUTICS
True North is guided by the needs of patients as we discover life-changing medicines for rare diseases. We combine scientific and clinical expertise in diseases of the Complement system so that we can rapidly develop new drugs for rare diseases with few, if any, treatment options. Our R&D is focused on finding novel drugs for rare diseases in which complement is a key driver of pathogenesis. We concentrate on therapies that can intervene upstream in the Complement system, selectively targeting the pathway underlying the disease.
A biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. The vaccine platform allows for the design of vaccines that closely mimic the target virus. VBI has also completed proof of concept thermostability studies on a number of vaccine and biologic.
A biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders utilizing the novel half-life extension technology, XTEN, in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD).
Zynerba Pharmaceuticals is dedicated to the development of next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery for patients with significant medical need. Their mission is to improve the lives of patients battling severe health conditions including peripheral neuropathic pain, fibromyalgia, chronic cancer pain, refractory epilepsy and osteoarthritis through synthetic cannabinoid therapeutics formulated for transdermal delivery.
AccuVein is a global leader in medical imaging solutions. Vein illumination with our breakthrough device, allows health care professionals to see a map of peripheral veins on the skin’s surface with the goal of improving venipuncture, the most commonly performed invasive medical procedure, and other vascular access procedures.
AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-based procedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare.
Alliqua Biomedical is a leading provider of advanced wound care solutions. The company is building a portfolio through targeted acquisitions and through licensing and distribution agreements with their strategic partner Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation.
CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.
We believe in the power of technology to make people healthier. Using just a small amount of saliva or blood, we can give you access to the information stored in your DNA and, most importantly, help you understand what it means. We’re working to make DNA screening just as simple, and just as common, as going to the doctor for a physical. By keeping costs low and providing results in straightforward, easy-to-understand language we’re putting potentially life-changing information within everyone’s reach.
Eidos Therapeutics is a clinical biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. Eidos seeks to treat this well-defined family of diseases at their collective source by stabilizing TTR.
Kadmon is a biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. Founded in 2009, Kadmon has pioneered a new approach to the traditional biotechnology model by building, from inception, a vertically integrated company comprising innovative drug discovery platforms, a deep clinical pipeline and a commercial operation with specialty pharmaceutical products.
Molecular Templates is focused on the discovery, development and commercialization of next generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancer. ETBs platform represents a new class of targeted biologic therapy with unique biological properties.
PTx has acquired the global rights to develop, manufacture, and commercialize Leukine from Sanofi. Leukine is a multi-lineage immune-stimulant that has been demonstrated to promote growth and activation of monocytes, macrophages, neutrophils and dendritic cells. It is the only FDA-approved recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF). Leukine is currently being tested in over 100 clinical studies to assess its ability to increase the efficacy of immuno-oncology therapies, improve the treatment of pulmonary and neurological disorders, and improve the treatment of infections. PTx is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer.
PROCEPT BioRobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. With an initial focus on benign prostatic hyperplasia (BPH), PROCEPT has developed Aquablation® therapy, a novel and disruptive treatment for enlarged prostate. The company’s first product, the AquaBeam® System, is the world’s first surgical robot providing autonomous tissue removal for the safe and effective treatment of BPH, independent of prostate anatomy or surgeon experience.
Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Sgx Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The Sgx Clarity system and Sgx Clarity assay received CE mark in 2017 and are commercially available in Europe; additional assays to detect and rule out infectious and inflammatory diseases are in development. Singulex is also developing a point-of-care platform and exploring applications beyond the clinical setting.
With breakthrough Multisonic Ultracleaning™ technology, Sonendo® is elevating the level of clean throughout endodontics and dentistry. By introducing broad spectrum acoustic technology and reducing doctors’ reliance on standard instrumentation, Sonendo is saving teeth, transforming dentistry and changing patients’ lives.
A clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. The company engineers and develops next-generation bispecific antibodies that bind with high specificity and affinity to certain cancer cells and direct the most potent cells of the human immune defense arsenal, to attack and kill cancer cells.
A biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, and for which there are currently limited patient options.
Headquartered in the heart of Silicon Valley, California, VitalConnect was founded in 2011 with a vision of changing the paradigm of healthcare as we know it by creating a new world of information with predictive data analytics at everyone’s fingertips.
At Medicrea, creativity is our highest priority, because we believe in the inventive power of our engineers and surgeon partners working together. (IM)PROVE. It extends from designing and manufacturing next-generation spinal implants, with enhanced functionalities and quality testing, to providing more effective and less invasive treatments for all spinal pathologies. Our aim is to restore the long-term quality of life for patients. Our extensive range of spinal implants addresses spinal pathologies at all levels, from cervical to lumbar and sacrum. Our implants are designed to treat scoliosis, degenerative deformation, trauma and tumors, regardless of severity, and can be used in all traditional and advanced surgical techniques, such as minimally-invasive surgery. We benefit from the support of renowned surgeons who are also closely involved in designing our prostheses as well as the support of healthcare agencies.
This leap forward in drug discovery allows Relay Therapeutics to leverage the relationship between protein motion and function, creating opportunities to develop more effective therapies for multiple diseases. Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
Rain Therapeutics aim to identify cancers with a single, and clear, oncogenic driver and evaluate sub-populations of cancer populations with an unmet need, where standards of care are ineffective.
4D MOLECULAR TEMPLATES
At 4DMT we are creating and developing optimized “biopharmaceutical grade” AAV vectors that will allow us uniquely to unlock the full potential of gene therapy. Our customized and proprietary AAV vectors are each designed, according to a 4DMT Target Vector Profile, to deliver genes to specific cells and tissues in the body to eradicate both rare and large market diseases.
Lyra Therapeutics is a clinical-stage company developing medicines precisely designed to target ear, nose and throat (ENT) diseases. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients.
Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, affect large patient populations and drive a significant portion of healthcare costs. Our main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide
The ReViral team has an extensive track record in the discovery and development of antiviral therapies. We work closely with key collaborators and consultants to transform the lives of patients and families affected by life-threatening viral infections.
Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, that can have a life-changing impact on cancer patients.
Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
We are a clinical stage biopharmaceutical company with the goal of curing cancer by developing targeted alpha therapeutics. We see targeted alpha therapeutics as the next generation of radiation therapy. We believe our proprietary Fast-Clear™ Technology Platform is a safer approach to targeted radiopharmaceuticals.
Kindbody believes that everyone should have access to convenient, affordable fertility and family-building care. They offer fertility and wellness services in modern, tech-enabled clinics, best-in-class care, accessible pricing, and a seamless patient experience.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer. We are a “start-up with a head start,” having launched in 2017 with a portfolio of promising clinical-stage therapies and with strong financial backing from a group of leading life science investors and pharmaceutical industry partners.
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hand-on approach to production and development that sets us apart.
ArcherDx proves a powerful product development platform for research that enables all molecular laboratories to solve complex genomic problems. Our ultimate goal is to break down barriers to sophisticated genomic analysis in community and regional settings with our in vitro diagnostic (IVD) products that are currently in development.
Icagen is an integrated early discovery partner, offering clients specialized technologies and deep scientific expertise to solve myriad challenges and optimize efficiency moving from target to lead. We work in multi-year, integrated programs, as well as individual projects to fill gaps in R&D efforts. The process begins with druggable targets, and our scientists bring exceptional experience in kinases, GPCR’s, ion channels and transporters. We work with clients to determine drug feasibility using state-of-the-art computational chemistry methods. Once a target is selected, we can combine virtual screening, ultra-high throughput screening (uHTS), biology and medicinal chemistry to generate viable leads in a much shorter time than has traditionally been possible.
Monteris is a private equity backed neurosurgical company focused solely on diseases of the brain. The company was founded in Winnipeg, Canada in 1999 to create neurosurgical technology that, when used by neurosurgeons, would allow them to ablate brain tumors and lesions that may be difficult to approach via traditional methods.
Since our 1997 founding, Saama’s goal has been to help clients access previously unattainable, enterprise-level views of the raw data across their disparate business silos. Today, that mission is empowering pharmaceutical and biotechnology companies to bring better drugs to market faster. Saama is the advanced clinical data analytics company unleashing insights from data for over 20 years, giving our life science client-partners the power to see around corners while making confident business decisions for better business outcomes.
Since our beginning in 2014, Freenome has had a clear vision—building a multi-disciplinary team with expertise in computational biology and machine learning techniques to reinvent disease management through early detection and precision intervention.
Exploiting the conformational complexity of GPCRs to innovate drug discovery. Confo Therapeutics employs its proprietary CONFO® technology to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery. Confobody-stabilized active state conformations of these receptors reveal previously inaccessible structural features empowering the discovery of novel pathway-selective agonists for improved therapeutic intervention.
We deliver genetic expertise to support everyone — from health care providers who need a trusted partner for genomic medicine to individuals interested in exploring their DNA.
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Progenitor cells are the natural sources of tissues throughout your body and remain present through adulthood. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering.
Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.
Kronos Bio is dedicated to the discovery and development of first-in-class therapies that modulate historically undruggable targets. We leverage deep capabilities in high-throughput small molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
Driving oncolytic virus therapy innovation for patients Oncolytic viruses (OVs) represent a new class of therapeutic agents in the arsenal of drugs against cancer. Oncorus has developed a robust OV platform, including a novel approach to maintain safety while enhancing oncolytic potency by leveraging the differential expression of micro-RNA (miR) sequences.
We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell therapeutics for patients with high unmet medical need.
Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.
At Chembio, our mission is to be a leader in the development, manufacture and commercialization of diagnostic solutions. We are dedicated to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). As a global company, we are committed to innovation and the highest quality standards.
DNAnexus has built the world’s most secure, trusted cloud platform and global network for scientific collaboration and accelerated discovery. We partner with customers to tackle the world’s most exciting opportunities in human health and beyond.
Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. to form VYNE Therapeutics, a different type of biopharmaceutical company working to solve some of today’s most difficult therapeutic challenges in dermatology and beyond.
Athira Pharma is a drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Our innovative approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality.
We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our industry expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.
THRIVE EARLIER DETECTION
We envision a future in which blood drawn at an annual physical is used to find early-stage cancer. When found early, cancer is often effectively treated or even cured. Our goal is to integrate early cancer screening into routine medical care, helping to provide navigation for the care process.
ATEA is a clinical stage biopharmaceutical company discovering and developing best-in-class therapies to address the unmet medical needs of patients with life-threatening viral diseases.
Nuvation Bio is a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology. Our vision is to significantly change the practice of oncology by developing medicines that provide truly meaningful improvements in quality of life and survival for people with cancer.
LianBio is a Chinese company focused on bringing paradigm shifting medicines to patients. LianBio leverages an unparalleled global innovation mining platform and China-centric execution strategy to enable partners to access large and dynamic healthcare landscape in China and major Asian markets while enhancing their global development initiatives.
Escient Pharmaceuticals is a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. We are focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs), and will initially pursue medicines for neuro-immuno-inflammatory and autoreactive diseases.
Prometheus Biosciences is a forward-thinking biopharmaceutical company that is dedicated to disrupting the treatment paradigm of GI diseases. We will do this by discovering and developing a broad portfolio of novel precision therapeutics and diagnostics that will meaningfully impact patient care.
Adiago Medical, Inc., a privately held medical device company located in Laguna Hills, California, is developing innovative cryoablation technologies that create continuous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventrical tachycardia.
Impulse Dynamics is a fast-growing medical device company that has pioneered a new form of therapy for heart failure called Cardiac Contractility Modulation, or CCM ™, which is delivered by the company’s Optimizer® Smart System.
Insightec is the pioneer and global leader in Focused Ultrasound, it’s their mission to help transform lives by delivering the therapeutic power of acoustic energy. With Insightec technology, sound waves are used to precisely target and ablate tissue with no incisions, little to no risk of infection, and patients often go home the same day — giving healthcare professionals a revolutionary approach to improving patient lives. They continue to collaborate and innovate, as researchers evaluate their technology in a range of clinical trials.
Omada uses the latest technology to bring real, human support to help people achieve their health goals through sustainable lifestyle change. Our customized digital care programs for prevention, type 2 diabetes, hypertension, and behavioral health address the whole person to empower healthy patterns that last.
C4 Therapeutics is committed to transforming the treatment of cancer, neurological and other important diseases with novel early stage therapies that eliminate disease-causing proteins. Our approach to medicine harnesses the innate machinery of the cell to attack disease and potentially bring deep and durable responses to pateints.
RLS (Radioisotope Life Sciences) sees itself as a key role player to facilitate the entry of new drugs and the installation of state of the art imaging equipment into the practice of health care. We also commit to expanding the market through alternative methods of production for Tc-99m and Ga-68.
Pear Therapeutics operates at the intersection of biology and software technology, where researchers and clinicians work side-by-side with software engineers and developers to create the next generation of therapeutics. We discover, develop, and deliver clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine.
AbSci is a leading synthetic biology company that translates ideas into drugs with a platform technology that reinvents the biopharmaceutical drug discovery process. We custom engineer E. coli to create novel complex biologics in their full length format while simultaneously developing production cell lines. We are deploying cutting edge deep learning artificial intelligence to inform our designs, and every day we succeed in achieving things others have dismissed as impossible. We are continually innovating, expanding the scope of what we can do and the impact we can have as we help get better medicines to patients…sooner.
Crossover makes remarkable health possible by connecting the disconnected. We bring people, their doctors, data, and benefits together under one Connected System of Health, partnering with health activist employers to provide care grounded in outcomes, not payment models. We use data to help keep your population healthy and to get ahead of chronic conditions. We leverage technology to unlock access and expand our impact.
We are taking sequencing further to bring you fast, powerful and flexible tools for research and precision medicine. Our aim is to empower scientists to answer their most pressing questions, allowing them to forge a path of discovery Without Limits.
Pyxis Oncology is devoted to transforming the lives of patients with cancer by advancing our innovative and differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies offer unique potential to address difficult-to-treat cancers, leading to improved patient outcomes.
At Amylyx our moments are spent in the pursuit of furthering treatment for those living with neurodegenerative diseases. Every day presents an opportunity to turn these rapidly progressing diseases into conditions that can be managed medically, and effectively. With the end goal of giving people more quality time with the ones they love.
Our vision is to take a major step forward in vaccine innovation to prevent and combat a wide range of infectious and other immune-mediated diseases, protecting infants and adults in our communities and making a meaningful impact on global public health.
Developing therapies with breakthrough rational design science. With our proprietary ART: Affinia Rationally-designed Therapies platform we generate a deep understanding of how structure impacts function to rationally design the gene therapies of tomorrow.
MIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures. Our innovative product portfolio provides physicians with unique devices that are designed to improve patient outcomes by reducing complications, shortening procedure times and expanding treatment to more patients.
At Twin Health, we invented the Whole Body Digital Health System to reverse and prevent multiple chronic metabolic diseases. Such diseases have a single root cause — a damaged metabolism. Human metabolism is so extremely complex and dynamic that until now it has not been possible to solve for the root cause. I realized the latest advancements in sensors, AI and digital twin technology can be combined with advanced medical science to precisely solve the root cause for the first time. This inspired us to create the Whole Body Digital Twin™.
Forge Medical offers a unique solution to obtaining patent hemostasis at a variety of access sites within the growing field of transradial coronary and noncoronary therapies.
BRIDGE TO LIFE
Bridge to Life was founded with the mission of improving organ transplants through licensing and developing new preservation solutions and technologies and providing the highest quality of service to organ procurement organizations and transplant centers.
Honor is the world’s largest home care network with the most advanced care platform. The Honor Care Platform combines local care, centralized operations, and best in class technology to deliver the highest quality care. This combination of human touch and technology can adapt and be tailored across our multiple home care networks. And it positions Honor to rapidly scale quality care for aging adults worldwide.
Emulate is overcoming the limitations of animal studies and reductionist models with living human in vitro models that empower researchers to explore the biological mechanisms of health and disease. These microphysiological systems (MPS), commonly known as Organ-Chips, are setting a new standard for how we study biology and develop drugs, therapies, and cures for those who need them most.
Synthego’s Genome Engineering Platforms deliver unprecedented scale and quality for gene editing tools and cell-based models to fuel your research at any stage. Engineering principles meet biology.
Trinity Biotech specializes in the development, manufacture and marketing of diagnostic test kits. The test kits they manufacture are used in the clinical laboratory and point-of-care segments of the diagnostic market, to detect infectious diseases, sexually transmitted diseases, autoimmune disorders, hemoglobin disorders, and in the detection, monitoring and control of diabetes. They are also a significant provider of raw materials to the life sciences industry. Quoted on the NASDAQ exchange, and with facilities spanning Europe and America, their products are sold in more than 110 countries.
Biodesix is a leading data-driven diagnostic solutions company helping answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies, with a primary focus in lung disease.
Hicuity Health has been at the forefront of transforming high acuity telemedicine. They innovated an independent tele-ICU model of care at their founding, extended that expertise to remote cardiac telemetry and more recently introduced remote device and wearables monitoring. Across a range of services, Hicuity offers clinical, technical, and operational expertise that supports hospitals nationwide in outstanding care of patients, care that is provably “Care. Innovated.”
O2 Concepts’ innovative portable oxygen concentrators (POCs) provide reliable, continuous flow — delivered in a leading-edge design with advanced technology, unmatched durability and extended battery life. Giving patients the effective oxygen therapy they deserve, with the mobility to live the life they desire.